EP
PBYI icon

Eversept Partners’s Puma Biotechnology PBYI Stock Holding History

Eversept Partners’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-240,688
Closed -$826K – 97
2025
Q2 		$826K Sell
240,688
-35,100
-13% -$112K 0.08% 64
2025
Q1 		$816K Sell
275,788
-720,314
-72% -$2.25M 0.08% 53
2024
Q4 		$3.04M Sell
996,102
-297,155
-23% -$865K 0.27% 49
2024
Q3 		$3.3M Sell
1,293,257
-35,197
-3% -$107K 0.23% 49
2024
Q2 		$4.33M Sell
1,328,454
-98,043
-7% -$430K 0.3% 48
2024
Q1 		$7.56M Sell
1,426,497
-268,524
-16% -$1.45M 0.5% 36
2023
Q4 		$7.34M Buy
1,695,021
+13,872
+0.8% +$46K 0.64% 31
2023
Q3 		$4.42M Buy
1,681,149
+22,954
+1% +$78.2K 0.37% 47
2023
Q2 		$5.85M Sell
1,658,195
-279,893
-14% -$873K 0.49% 38
2023
Q1 		$5.99M Buy
1,938,088
+430,425
+29% +$1.62M 0.42% 39
2022
Q4 		$6.38M Buy
1,507,663
+1,958
+0.1% +$6.76K 0.56% 37
2022
Q3 		$3.57M Buy
1,505,705
+70,628
+5% +$206K 0.31% 42
2022
Q2 		$4.09M Buy
1,435,077
+10,427
+0.7% +$25.9K 0.29% 50
2022
Q1 		$4.1M Buy
1,424,650
+306,752
+27% +$793K 0.32% 51
2021
Q4 		$3.4M Buy
1,117,898
+719,958
+181% +$3.12M 0.22% 71
2021
Q3 		$2.79M Buy
+397,940
New +$2.98M 0.19% 66
2020
Q2 		– Sell
-58,251
Closed -$492K – 78
2020
Q1 		$492K Buy
+58,251
New +$566K 0.12% 55
2019
Q1 		– Sell
-42,301
Closed -$861K – 60
2018
Q4 		$861K Buy
42,301
+20,630
+95% +$619K 0.47% 38
2018
Q3 		$994K Sell
21,671
-2,253
-9% -$109K 0.44% 35
2018
Q2 		$1.42M Buy
23,924
+1,000
+4% +$58K 0.65% 33
2018
Q1 		$1.56M Sell
22,924
-31,725
-58% -$2.38M 0.72% 29
2017
Q4 		$5.4M Buy
+54,649
New +$6.12M 3.11% 13

Other funds holding PBYI

ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return

Eversept Partners's PBYI Position: Q3 2025 in Review

Eversept Partners sold out of Puma Biotechnology (PBYI) in Q3 2025, closing a stake of 240,688 shares — an estimated $826K sold.

Eversept Partners first reported a position in PBYI in Q4 2017 and held it in 22 quarters. The position peaked at $7.56M in Q1 2024. 132 funds tracked by Wall St. Rank hold PBYI as of Q3 2025.

  • Eversept Partners reported no remaining Puma Biotechnology position as of Q3 2025 after selling out during the quarter.
  • Eversept Partners sold 240,688 Puma Biotechnology shares in Q3 2025, an estimated $826K.
  • Eversept Partners first reported a position in Puma Biotechnology in Q4 2017 and held it in 22 quarters.
  • Eversept Partners's Puma Biotechnology position peaked at $7.56M in Q1 2024.
  • 132 funds tracked by Wall St. Rank held Puma Biotechnology as of Q3 2025.

Based on Eversept Partners's 13F filing for Q3 2025, filed 14 Nov 2025.